Literature DB >> 27411403

Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Julian O M Ormerod1, Michael P Frenneaux2, Mark V Sherrid3.   

Abstract

Evidence indicates that anatomical and physiological phenotypes of hypertrophic cardiomyopathy (HCM) stem from genetically mediated, inefficient cardiomyocyte energy utilization, and subsequent cellular energy depletion. However, HCM often presents clinically with normal left ventricular (LV) systolic function or hyperkinesia. If energy inefficiency is a feature of HCM, why is it not manifest as resting LV systolic dysfunction? In this Perspectives article, we focus on an idiosyncratic form of reversible systolic dysfunction provoked by LV obstruction that we have previously termed the 'lobster claw abnormality' - a mid-systolic drop in LV Doppler ejection velocities. In obstructive HCM, this drop explains the mid-systolic closure of the aortic valve, the bifid aortic pressure trace, and why patients cannot increase stroke volume with exercise. This phenomenon is characteristic of a broader phenomenon in HCM that we have termed dynamic systolic dysfunction. It underlies the development of apical aneurysms, and rare occurrence of cardiogenic shock after obstruction. We posit that dynamic systolic dysfunction is a manifestation of inefficient cardiomyocyte energy utilization. Systolic dysfunction is clinically inapparent at rest; however, it becomes overt through the mechanism of afterload mismatch when LV outflow obstruction is imposed. Energetic insufficiency is also present in nonobstructive HCM. This paradigm might suggest novel therapies. Other pathways that might be central to HCM, such as myofilament Ca2+ hypersensitivity, and enhanced late Na+ current, are discussed.

Entities:  

Mesh:

Year:  2016        PMID: 27411403     DOI: 10.1038/nrcardio.2016.98

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  94 in total

1.  Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.

Authors:  R Lodi; J M Cooper; J L Bradley; D Manners; P Styles; D J Taylor; A H Schapira
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy.

Authors:  K Okeie; M Shimizu; H Yoshio; H Ino; M Yamaguchi; T Matsuyama; T Yasuda; J Taki; H Mabuchi
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

3.  Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.

Authors:  Stefan A J Timmer; Tjeerd Germans; Wessel P Brouwer; Mark Lubberink; Jolanda van der Velden; Arthur A M Wilde; Imke Christiaans; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Heart Fail       Date:  2011-10-21       Impact factor: 15.534

4.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

Review 5.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

6.  Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

Authors:  Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

7.  Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia.

Authors:  Michael Bunse; Nana Bit-Avragim; Axel Riefflin; Andreas Perrot; Oliver Schmidt; Friedmar R Kreuz; Rainer Dietz; Wulf-Ingo Jung; Karl Josef Osterziel
Journal:  Ann Neurol       Date:  2003-01       Impact factor: 10.422

8.  Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction.

Authors:  Sairia Dass; Lowri E Cochlin; Joseph J Suttie; Cameron J Holloway; Oliver J Rider; Leah Carden; Damian J Tyler; Theodoros D Karamitsos; Kieran Clarke; Stefan Neubauer; Hugh Watkins
Journal:  Eur Heart J       Date:  2015-05-18       Impact factor: 29.983

9.  Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation.

Authors:  E Rosalie Witjas-Paalberends; Claudia Ferrara; Beatrice Scellini; Nicoletta Piroddi; Judith Montag; Chiara Tesi; Ger J M Stienen; Michelle Michels; Carolyn Y Ho; Theresia Kraft; Corrado Poggesi; Jolanda van der Velden
Journal:  J Physiol       Date:  2014-06-13       Impact factor: 5.182

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  4 in total

Review 1.  Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure.

Authors:  Waqas T Qureshi; Usama Bin Nasir
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

Review 2.  Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy.

Authors:  Richard J Marszalek; R John Solaro; Beata M Wolska
Journal:  Pflugers Arch       Date:  2018-10-29       Impact factor: 3.657

3.  Impaired Right Ventricular Mechanics at Rest and During Exercise Are Associated With Exercise Capacity in Patients With Hypertrophic Cardiomyopathy.

Authors:  Xiao-Peng Wu; Yi-Dan Li; Yi-Dan Wang; Miao Zhang; Wei-Wei Zhu; Qi-Zhe Cai; Wei Jiang; Lan-Lan Sun; Xue-Yan Ding; Xiao-Guang Ye; Yun-Yun Qin; Xiu-Zhang Lu
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

4.  HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.

Authors:  Laetitia Dard; Christophe Hubert; Pauline Esteves; Wendy Blanchard; Ghina Bou About; Lyla Baldasseroni; Elodie Dumon; Chloe Angelini; Mégane Delourme; Véronique Guyonnet-Dupérat; Stéphane Claverol; Laura Fontenille; Karima Kissa; Pierre-Emmanuel Séguéla; Jean-Benoît Thambo; Lévy Nicolas; Yann Herault; Nadège Bellance; Nivea Dias Amoedo; Frédérique Magdinier; Tania Sorg; Didier Lacombe; Rodrigue Rossignol
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.